Evidence map›Paper›PMID 35898390›Full record

ArticleClinical Medicine Insights. Oncology2022

The m6A RNA Modification Quantity and the Prognostic Effect of Reader YTHDC2 in Colorectal Cancer.

Tianyu Liu, Wentao Tang, Yijiao Chen, Yu Liu, Donghao Xu, Yudong Jiang, Shizhao Zhou, Xiaorui Qin, Li Ren, Wenju Chang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Tianyu LiuColorectal Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0001-5174-2539
Wentao TangColorectal Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yijiao ChenColorectal Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu LiuColorectal Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Donghao XuColorectal Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yudong JiangColorectal Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-9405-4100
Shizhao ZhouColorectal Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaorui QinColorectal Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Li RenColorectal Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Wenju ChangColorectal Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Jianmin XuColorectal Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: N6-methyladenosine (m6A) modification plays crucial roles in cancers. However, its alteration in colorectal cancer (CRC) is still poorly described. The purpose of this study is to explore the change of m6A modification and the function of m6A binding protein YTHDC2 in CRC. Methods: The global level of m6A modification was detected by mass spectrometry and dot blotting assay. The expression of YTHDC2 was investigated using The Cancer Genome Atlas and using real-time polymerase chain reaction (RT-qPCR), western blotting, and immunohistochemistry based on CRC tissues. Kaplan-Meier analysis and Cox proportional hazards regression were performed to analyze the prognostic value of YTHDC2. RNA immunoprecipitation (RIP)-seq and m6A immunoprecipitation (MeRIP)-seq were used to explore the direct targets of YTHDC2. Gene oncology (GO) and Gene Set Enrichment Analysis (GSEA) were used to explore the pathways that could be influenced by YTHDC2. Results: No significant difference was observed in the global level of m6A modification on total RNA or mRNA between CRC and adjacent nontumor tissues. We further found a significant decreasing of YTHDC2 in CRC tissues. Kaplan-Meier analysis indicated that lower expression of YTHDC2 was related to the worse disease-free survival and overall survival. In addition, lower expression of YTHDC2 was an independent worse prognostic factor in univariate and multivariate Cox regression analysis. Using YTHDC2-RIP-seq and MeRIP-seq, we identified that YTHDC2 could participate in several important biological signal pathways. Conclusions: In summary, this study suggested that the global level of m6A did not change in CRC and identified that lower YTHDC2 as a prognostic marker for worse survival of CRC.

Indexed as

Colorectal cancerN6-methyladenosineprognostic biomarkerRNA modificationYTHDC2

Identifiers

PMID35898390
PMCPMC9310211
OpenAlexW4286728531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.